EBRT with or without STAD showed similar 15-year PCSS and OS rates in IRPC patients, with high PSA failure rates observed. Multivariate analysis indicated greater side effects in the STAD group ...
Credit: Getty Images Aglatimagene besadenovec (CAN-2409) is a replication-defective adenoviral vector carrying the herpes simplex virus thymidine kinase gene. In a phase 3 trial, adding aglatimagene ...
Adjuvant EBRT after RP may prolong biochemical PFS and MFS but not OS in patients with positive surgical margins, extracapsular extension, or seminal vesicle invasion, supporting a shared ...
Adding supplemental external beam radiotherapy (EBRT) did not improve outcomes in higher-risk cancer patients who had brachytherapy, according to the long-term results of two trials. Specifically, ...
Long-term results from a phase 3 study showed that adding a focal boost to standard external beam radiotherapy (EBRT) improved 10-year biochemical disease-free survival (DFS) and reduced biochemical ...
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk prostate cancer treated with external-beam radiation therapy (EBRT), ...
Risk factors like Gleason score, cancer stage, PSA levels, and genetic markers guide prostate cancer treatment decisions. Treatment options include active surveillance, surgery, radiation, hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results